Newsletter #2 - Mar 2021 - Trial 0204 and 0206, and Company presentations
The HEAT is on...
Starting three  clinical trials in one year, requires a lot of effort for a small company - and we are happy with the progress. The first 3 months have been fantastic - apart from being awarded best Nordic IPO earlier this month, we announced the top-line results of the Registry Safety Study and initiated Trial 0204. Many have asked us, when we hear more about the company, and we will soon communicate and advertise more about our progress...we just needed to get it all starting. Thank you for having patience.
Major milestone #2 - Trial 0204 (and soon Trial 0206)
Trial 0204 was initiated earlier this month, and we have spent much time preparing for this, and we very happy with our decisions. Conducting clinical trials is really a lot about preparation, and this has not been that easy during COVID19. However, we anticipate to be done earlier than planned, so hopefully we will close the study in Q2 this year. This would be a fantastic achievement by the teams involved. In addition, we also hope to be ready with Trial 0206 - hopefully we can also initiate this in Q2, the third important milestone of 2021
Milestone #1, the Registry Safety Study - Favourable data
Data from the Registry Safety Study (0203) was announced earlier this month, and indicates a favourable safety-profile for Cessatech’s lead product CT001. The primary outcome of the Registry Safety Study has been to investigate adverse events, including serious adverse events for the combination of sufentanil and s-ketamine when administered as a part of routine clinical care. No serious adverse events were reported, confirming a favourable safety profile for this combination. With the intended use of this combination in elective children as well as in emergency cases, safety is perhaps even more pivotal for a successful and efficient outcome
Cessatech - Company presentations
We will intensify the communication about the company and its progress in the coming months and especially in the 2nd half of the year - remember we were capitalized in December 2020. We have been off to a good start and are now ready to increase the communication. Our first company presentation will be on the Nordnet Live platform on 15 April - please see link below. Secondly, we have confirmed a presentation with Økonomisk Ugebrev in October, and more will be announced during the year once they have been confirmed. Please have a look at the calendar events
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.